Drug Profile


Alternative Names: APL2

Latest Information Update: 07 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Apellis Pharmaceuticals
  • Class Antianaemics; Cyclic peptides; Eye disorder therapies
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry age-related macular degeneration
  • Phase I Ischaemia; Paroxysmal nocturnal haemoglobinuria; Wet age-related macular degeneration

Most Recent Events

  • 26 Jul 2017 Apellis Pharmaceuticals plans a phase II trial for Autoimmune haemolytic anaemia (NCT03226678)
  • 10 Jul 2017 Apellis Pharmaceuticals plans to initiate a phase I trial in Paroxysmal nocturnal hemoglobinuria (In volunteers) in Australia (ACTRN12617000982314p)
  • 29 Jun 2017 Positive efficacy and adverse events data from the phase I PADDOCK and PHAROAH trial in Paroxysmal nocturnal hemoglobinuria released by Apellis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top